BioRegenx : Non Reliance on Previously Issued Financial Report Form 8 K
June 11, 2024 at 11:06 am
Share
Item 4.01 Changes in Registrant's Certifying Accountants.
(b) Appointment of Independent Registered Public Accounting Firm.
On June 10, 2024, BioRegenx, Inc. (the "Company") engaged and executed an agreement with Weinberg & Company, P.A. ("Weinberg), as the Company's new independent accountant for the fiscal years ended December 31, 2023 and 2022. The board of directors approved the decision to engage Weinberg.
During the Company's fiscal years ended December 31, 2023 and 2022, and the subsequent interim period through June 10, 2024, neither the Company nor anyone on its behalf consulted with Weinberg on either (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the consolidated financial statements of the Company and its subsidiaries, and no written report or oral advice was provided by Weinberg to the Company that Weinberg concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (b) any matter that was the subject of either a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).
Attachments
Original Link
Permalink
Disclaimer
Findit Inc. published this content on
11 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
11 June 2024 10:05:22 UTC.
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Companyâs patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.
BIOREGENX, INC. 
